- Home
- COYA vs NTRB Comparison
COYA vs NTRB Comparison
Compare COYA & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- NTRB
- Stock Information
- Founded
- COYA 2020
- NTRB 2016
- Country
- COYA United States
- NTRB United States
- Employees
- COYA N/A
- NTRB N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- COYA Health Care
- NTRB Health Care
- Exchange
- COYA Nasdaq
- NTRB Nasdaq
- Market Cap
- COYA 98.5M
- NTRB 84.1M
- IPO Year
- COYA 2022
- NTRB N/A
- Fundamental
- Price
- COYA $6.41
- NTRB $7.46
- Analyst Decision
- COYA Strong Buy
- NTRB Buy
- Analyst Count
- COYA 4
- NTRB 1
- Target Price
- COYA $16.25
- NTRB $13.00
- AVG Volume (30 Days)
- COYA 92.0K
- NTRB 215.9K
- Earning Date
- COYA 03-18-2025
- NTRB 12-04-2024
- Dividend Yield
- COYA N/A
- NTRB N/A
- EPS Growth
- COYA N/A
- NTRB N/A
- EPS
- COYA N/A
- NTRB N/A
- Revenue
- COYA $9,554,315.00
- NTRB $2,021,771.00
- Revenue This Year
- COYA N/A
- NTRB $7.95
- Revenue Next Year
- COYA $56.22
- NTRB $538.25
- P/E Ratio
- COYA N/A
- NTRB N/A
- Revenue Growth
- COYA N/A
- NTRB N/A
- 52 Week Low
- COYA $4.75
- NTRB $2.22
- 52 Week High
- COYA $10.69
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- COYA 52.07
- NTRB 55.21
- Support Level
- COYA $5.85
- NTRB $6.68
- Resistance Level
- COYA $7.25
- NTRB $8.24
- Average True Range (ATR)
- COYA 0.51
- NTRB 0.74
- MACD
- COYA -0.04
- NTRB -0.11
- Stochastic Oscillator
- COYA 32.94
- NTRB 43.32
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.